Boston Partners’s Anika Therapeutics ANIK Stock Holding History

Boston Partners’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-28,852	Closed	-$733K	–	708
2024 Q1	$733K	Buy	+28,852	New	+$698K	﹤0.01%	632

Other funds holding ANIK

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boston Partners's ANIK Position: Q2 2024 in Review

Boston Partners sold out of Anika Therapeutics (ANIK) in Q2 2024, closing a stake of 28,852 shares — an estimated $733K sold.

Boston Partners first reported a position in ANIK in Q1 2024 and held it in 1 quarter. The position peaked at $733K in Q1 2024. 114 funds tracked by Wall St. Rank hold ANIK as of Q2 2024.

Boston Partners reported no remaining Anika Therapeutics position as of Q2 2024 after selling out during the quarter.
Boston Partners sold 28,852 Anika Therapeutics shares in Q2 2024, an estimated $733K.
Boston Partners first reported a position in Anika Therapeutics in Q1 2024 and held it in 1 quarter.
Boston Partners's Anika Therapeutics position peaked at $733K in Q1 2024.
114 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2024.

Based on Boston Partners's 13F filing for Q2 2024, filed 14 Aug 2024.